Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model

Cornea

Volumn 15, Issue 1, 1996, Pages 76-81

  Olsen, Timothy W ^a   Gothard, Todd W ^a   Holland, Edward J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Allograft; Cyclosporine; Keratoplasty; Misoprostol; Rejection

Indexed keywords

CYCLOSPORIN A; MISOPROSTOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORNEA TRANSPLANTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME;

EID: 0030046372     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-199601000-00014     Document Type: Article

References (22)

1. Hill JC, Maske R. An animal model for corneal graft rejection in high risk keratopiasty. Transplantation 1988;46:26- 30.
2. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989;107:506-10.
3. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993;12:413-9.
4. Ballardie FW, Edwards BD, Hows J, Jones L, Peters AM. Disturbances in renal hemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A. Nephron 1992;60:17-24.
5. Keown P, Stiller C, Ulan R. Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet 1981;1:686.
6. Nussenblatt RB, Palestine AG. Cyclosporin: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986; 31:159-69.
7. Harding MW, Handschumacher RE. Cyclophilin, a primary target molecule for cyclosporine: structural and functional implications. Transplantation 1988;46:29S
8. Foxwell BMJ, Ruffel B. The mechanisms of action of cyclosporine. Cardiol Clin 1990;8:107-117.
9. Granelli-Piperno A, Andrus L, Steinman RM. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells: kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med 1986;163:922-37.
10. Ueda H, Wayne HW, Yuk-Chun C, et al. The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts. Transplantation 1990;50:545-50
11. Klaus GGB, Hawrylowicz CM. Activation and proliferation signals in mouse B cells II. Evidence for activation (G0 to G1) signals differing in sensitivity to cyclosporine. Eur J Immunol 1984;14:250-4.
12. Wilson DE, Quadros E, Rajapaksa T, Adams A, Noar M. Effects of misoprostol on gastric acid and mucous secretion in man. Dig Dis Sci 1986;31(suppl): 126-9.
13. Goodwin JS, Messner RP, Peake GT. Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. J Clin Invest 1978;62:753-60.
14. Wiederkehr JC, Dumble L, Pollak R, Moran M. Immunosuppressive effect of misoprostol: a new synthetic prostaglandin E1 analogue. Aust N Z J Surg 1990;60:121-4.
15. Moran M, Mozes MF, Maddux MS, et al. Prevention of acute graft rejection by the prostaglandin El analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med 1990;322:1183-8.
16. Pollak R, Dumble LJ, Wiederkehr JC, Maddux MS, Moran M. The immunosuppressive properties of new oral prostaglandin El analogs. Transplantation 1990;50:834-8.
17. Iyengar S, Contreras PC, Mick SJ, Bremer ME, McKearn JP. Immune modifying effects of misoprostol and natural prostaglandins. Br J Rhematol 1991;30(suppl 2):71-4.
18. Holland EJ, Olsen TW, Sterrer J, Ketchum JM, Mindrup EA, Gruber SA. Suppression of graft rejection using 15- deoxyspergualin in the allogeneic rat penetrating keratoplasty model. Cornea 1994;13:28-32.
19. Moncada S, Flaver RL, Vane JR. Prostaglandins, prostacyclin and thromboxane A2. In: Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980:668-81.
20. Paller MS. Effects of the prostaglandin El analog misoprostol on cyclosporine nephrotoxicity. Transplantation 1988;45:1126-31.
21. Tobimatsu M, Konomi K, Saito S, Tsumagari T. Protective effect of prostaglandin E1 on ischemia-induced acute renal failure in dogs. Surgery 1985;98:45-53.
22. Aspinall RL, Cammarata PS, Nakao A, et al. Effect of various prostaglandins on two laboratory models of chronic arthritic inflammation. Adv Biosci 1969;24:419-23.